Fluad-Stanford University-influenza-hepatitis A-typhoid fever

This research regimen is a combination of several distinct vaccines utilized in a Phase 1 mechanistic study (SLVP033) conducted by Stanford University. The study is designed to evaluate the longitudinal effects of aging on the human immune system by comparing primary and secondary vaccine responses in younger (18-40 years) and older (≥65 years) adults. The regimen includes **Fluad** (an MF59-adjuvanted influenza vaccine), **Vaqta** (an inactivated hepatitis A vaccine), and typhoid vaccines (**Typhim Vi** or **Vivotif**). By administering these vaccines, researchers can observe recall immune responses to influenza alongside de novo responses to hepatitis A and typhoid, providing insights into age-related immune senescence and the molecular signatures of impaired vaccine efficacy in the elderly.

Brand names

FluadVaqtaTyphim ViVivotifFluzone High DoseFluzone quadrivalent

Other names

Fluad-Stanford University-influenza-hepatitis A-typhoid feverEffects of Aging on Vaccine Responses Study Regimen